Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.55M | 26.08M | 14.42M | 13.79M | 10.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.55M | 26.08M | 14.42M | 13.79M | 10.89M |
| Cost of Revenue | 111.13M | 86.68M | 83.13M | 78.73M | 79.36M |
| Gross Profit | -106.58M | -60.60M | -68.71M | -64.93M | -68.47M |
| SG&A Expenses | 77.29M | 37.76M | 31.83M | 31.30M | 31.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 188.42M | 124.44M | 114.96M | 110.03M | 111.01M |
| Operating Income | -183.88M | -98.35M | -100.54M | -96.23M | -100.12M |
| Income Before Tax | -178.90M | -95.68M | -98.06M | -92.15M | -97.06M |
| Income Tax Expenses | 7.00K | 167.00K | -523.00K | -779.00K | -4.06M |
| Earnings from Continuing Operations | -178.91M | -95.84M | -97.54M | -91.37M | -93.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.91M | -95.84M | -97.54M | -91.37M | -93.00M |
| EBIT | -183.88M | -98.35M | -100.54M | -96.23M | -100.12M |
| EBITDA | -170.93M | -91.16M | -91.58M | -88.86M | -92.57M |
| EPS Basic | -0.53 | -0.34 | -0.40 | -0.39 | -0.42 |
| Normalized Basic EPS | -0.33 | -0.21 | -0.25 | -0.24 | -0.28 |
| EPS Diluted | -0.54 | -0.34 | -0.40 | -0.39 | -0.42 |
| Normalized Diluted EPS | -0.33 | -0.21 | -0.25 | -0.24 | -0.28 |
| Average Basic Shares Outstanding | 336.04M | 282.58M | 242.20M | 236.02M | 223.16M |
| Average Diluted Shares Outstanding | 336.04M | 282.58M | 242.20M | 236.02M | 223.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
